KR100604176B1 - 신경증성 질환의 치료 - Google Patents

신경증성 질환의 치료 Download PDF

Info

Publication number
KR100604176B1
KR100604176B1 KR1020017016006A KR20017016006A KR100604176B1 KR 100604176 B1 KR100604176 B1 KR 100604176B1 KR 1020017016006 A KR1020017016006 A KR 1020017016006A KR 20017016006 A KR20017016006 A KR 20017016006A KR 100604176 B1 KR100604176 B1 KR 100604176B1
Authority
KR
South Korea
Prior art keywords
treatment
medicament
agent
test
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020017016006A
Other languages
English (en)
Korean (ko)
Other versions
KR20020015346A (ko
Inventor
산체즈코니에
호그산드라
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8099796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100604176(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20020015346A publication Critical patent/KR20020015346A/ko
Application granted granted Critical
Publication of KR100604176B1 publication Critical patent/KR100604176B1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020017016006A 1999-07-08 2000-07-07 신경증성 질환의 치료 Ceased KR100604176B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900991 1999-07-08
DKPA199900991 1999-07-08

Publications (2)

Publication Number Publication Date
KR20020015346A KR20020015346A (ko) 2002-02-27
KR100604176B1 true KR100604176B1 (ko) 2006-07-25

Family

ID=8099796

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017016006A Ceased KR100604176B1 (ko) 1999-07-08 2000-07-07 신경증성 질환의 치료

Country Status (38)

Country Link
US (6) US7271194B2 (https=)
EP (4) EP1440691A3 (https=)
JP (1) JP4773011B2 (https=)
KR (1) KR100604176B1 (https=)
CN (1) CN1198610C (https=)
AR (1) AR021155A1 (https=)
AT (1) ATE339955T1 (https=)
AU (6) AU782514B2 (https=)
BG (4) BG106279A (https=)
BR (1) BR0011578A (https=)
CA (4) CA2687396A1 (https=)
CL (3) CL2008003941A1 (https=)
CO (1) CO5190674A1 (https=)
CY (1) CY1105806T1 (https=)
CZ (1) CZ200270A3 (https=)
DE (1) DE60030861T2 (https=)
DK (1) DK1200081T3 (https=)
EA (1) EA006555B1 (https=)
ES (1) ES2272298T3 (https=)
HK (1) HK1048069B (https=)
HR (1) HRP20010820A2 (https=)
HU (1) HUP0201791A3 (https=)
IL (5) IL146131A0 (https=)
IS (1) IS6137A (https=)
ME (2) MEP2508A (https=)
MX (1) MXPA01011626A (https=)
MY (1) MY143278A (https=)
NO (4) NO329021B1 (https=)
PL (1) PL352030A1 (https=)
PT (1) PT1200081E (https=)
SI (1) SI1200081T1 (https=)
SK (1) SK82002A3 (https=)
TR (4) TR200402275T2 (https=)
TW (1) TWI232101B (https=)
UA (1) UA77645C2 (https=)
WO (1) WO2001003694A1 (https=)
YU (1) YU78701A (https=)
ZA (1) ZA200108856B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
WO2002008216A1 (en) 2000-07-21 2002-01-31 H. Lundbeck A/S Novel compounds and their use as glycine transport inhibitors
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
BR0206164A (pt) 2001-07-31 2003-10-28 Lundbeck & Co As H Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
WO2004004721A1 (en) * 2002-07-08 2004-01-15 University Of Florida Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders
UA80170C2 (en) * 2002-12-23 2007-08-27 Lundbeck & Co As H Escitalopram hydrobromide
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
US20050154052A1 (en) * 2003-03-24 2005-07-14 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1954257A4 (en) 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (https=) 1965-03-18
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4439545A (en) 1981-11-19 1984-03-27 Societe D "Expansion Scientifique "Expansia" Acrylic copolymers of N-acryloylpolymethyleneimines or N-acryloyldialkylamides, N,N'-acryloyldiaminoalcanes and N-acryloylaminoacids (or esters) their preparation and use as cation exchangers
GB8419963D0 (en) 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DK213290D0 (da) 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
ATE244563T1 (de) 1991-11-15 2003-07-15 Sepracor Inc Verwendung von reinem fluoxetin-s(+)-isomer für die herstellung eines medikements gegen migräne
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1996024353A1 (en) * 1995-02-10 1996-08-15 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) 1995-04-27 1995-04-27 Astra Ab A new combination
ATE192042T1 (de) 1995-08-16 2000-05-15 Lilly Co Eli Potenzierung von serotonin-wirkstoffresponz
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) * 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703379D0 (sv) * 1997-09-18 1997-09-18 Astra Ab New compounds
EP1042310B1 (en) * 1997-11-11 2002-07-31 H. Lundbeck A/S Method for the preparation of citalopram
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
EP1100501A4 (en) * 1998-06-30 2002-12-04 Lilly Co Eli PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN
AU771252B2 (en) 1998-07-13 2004-03-18 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression and other disorders
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
JP2002520353A (ja) 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
SE9803157D0 (sv) 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
CA2291134C (en) * 1998-10-20 2006-05-23 H. Lundbeck A/S Method for the preparation of citalopram
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2002361405A (ja) * 2000-09-25 2002-12-18 Showa Denko Kk 熱交換器の製造方法
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама

Also Published As

Publication number Publication date
TR200402276T2 (tr) 2005-01-24
HK1048069B (zh) 2005-12-16
HUP0201791A3 (en) 2005-02-28
EP1440691A3 (en) 2004-08-25
BG110467A (en) 2010-01-29
EP1440690A3 (en) 2004-08-18
AU2005202686A1 (en) 2005-07-14
MY143278A (en) 2011-04-15
CL2008003939A1 (es) 2009-06-05
CA2373757A1 (en) 2001-01-18
IL170194A (en) 2010-05-31
IS6137A (is) 2001-10-30
CN1360501A (zh) 2002-07-24
CA2687392A1 (en) 2001-01-18
WO2001003694A1 (en) 2001-01-18
MXPA01011626A (es) 2002-06-04
CY1105806T1 (el) 2011-02-02
CL2008003941A1 (es) 2009-05-22
NO20100335L (no) 2002-01-07
US20050101665A1 (en) 2005-05-12
AU2005202684B2 (en) 2009-01-15
NO20020062D0 (no) 2002-01-07
ATE339955T1 (de) 2006-10-15
DE60030861D1 (de) 2006-11-02
AU2005202684A1 (en) 2005-07-14
EA200200137A1 (ru) 2002-06-27
BR0011578A (pt) 2002-03-26
AU5806100A (en) 2001-01-30
CA2687396A1 (en) 2001-01-18
TWI232101B (en) 2005-05-11
IL146131A0 (en) 2002-07-25
NO20100334L (no) 2002-01-07
CA2373757C (en) 2010-01-05
NO329021B1 (no) 2010-07-26
NO20020062L (no) 2002-01-07
SI1200081T1 (sl) 2007-02-28
BG106279A (bg) 2002-08-30
SK82002A3 (en) 2002-07-02
AU782514B2 (en) 2005-08-04
EP1440690A2 (en) 2004-07-28
ES2272298T3 (es) 2007-05-01
EP1200081A1 (en) 2002-05-02
BG110466A (en) 2010-01-29
HRP20010820A2 (en) 2003-08-31
DE60030861T2 (de) 2007-05-03
PT1200081E (pt) 2007-01-31
MEP2508A (xx) 2010-02-10
PL352030A1 (en) 2003-07-28
EP1200081B1 (en) 2006-09-20
CO5190674A1 (es) 2002-08-29
US20070276035A1 (en) 2007-11-29
AU2005202686B2 (en) 2009-01-15
EP1440691A2 (en) 2004-07-28
EP1440689A3 (en) 2004-08-25
ME00032B (me) 2010-02-10
ZA200108856B (en) 2002-12-24
UA77645C2 (en) 2007-01-15
CA2687394A1 (en) 2001-01-18
US20040029956A1 (en) 2004-02-12
AU2008264182A1 (en) 2009-01-29
YU78701A (sh) 2004-03-12
AU2008264188A1 (en) 2009-05-07
US20040029958A1 (en) 2004-02-12
JP4773011B2 (ja) 2011-09-14
US20020086899A1 (en) 2002-07-04
IL170192A (en) 2010-04-29
EP1440689A2 (en) 2004-07-28
US7265151B2 (en) 2007-09-04
TR200402277T2 (tr) 2005-01-24
US20040029957A1 (en) 2004-02-12
CZ200270A3 (cs) 2002-04-17
AR021155A1 (es) 2002-06-12
US7271194B2 (en) 2007-09-18
CN1198610C (zh) 2005-04-27
US6960613B2 (en) 2005-11-01
IL146131A (en) 2007-02-11
BG110468A (en) 2010-01-29
DK1200081T3 (da) 2006-12-27
HK1048069A1 (en) 2003-03-21
KR20020015346A (ko) 2002-02-27
IL170193A (en) 2010-04-29
NO20100333L (no) 2002-01-07
AU2005202685B2 (en) 2009-01-15
AU2005202685A1 (en) 2005-07-14
CL2008003938A1 (es) 2009-05-22
TR200200014T2 (tr) 2002-05-21
HUP0201791A2 (en) 2002-10-28
JP2003504332A (ja) 2003-02-04
TR200402275T2 (tr) 2005-03-21
EA006555B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
US20070276035A1 (en) Treatment of neurotic disorders
EA008373B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA008372B1 (ru) Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20011212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040610

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20051214

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20060426

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20060718

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20060719

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20080219

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20060718

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20080219

Decision date: 20090827

Appeal identifier: 2008100000473

FPAY Annual fee payment

Payment date: 20090708

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20090708

Start annual number: 4

End annual number: 4

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20080219

Effective date: 20090827

Free format text: TRIAL NUMBER: 2008100000473; TRIAL DECISION FOR INVALIDATION REQUESTED 20080219

Effective date: 20090827

PJ1301 Trial decision

Patent event code: PJ13011S05D

Patent event date: 20090827

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20080219

Decision date: 20090827

Appeal identifier: 2008100000473

J2X1 Appeal (before the patent court)

Free format text: INVALIDATION

Free format text: TRIAL NUMBER: 2009200007710; INVALIDATION

PJ2001 Appeal

Patent event date: 20090827

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Appeal kind category: Invalidation

Decision date: 20101223

Appeal identifier: 2009200007710

Request date: 20091028

FPAY Annual fee payment

Payment date: 20100712

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20100712

Start annual number: 5

End annual number: 5

EXTG Ip right invalidated
PC2102 Extinguishment

Termination category: Others

Termination date: 20110215

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20091028

Effective date: 20101223

Free format text: TRIAL NUMBER: 2009200007710; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20091028

Effective date: 20101223

PJ1302 Judgment (patent court)

Patent event date: 20110215

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20091028

Decision date: 20101223

Appeal identifier: 2009200007710

Appeal kind category: Invalidation

G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction

Publication date: 20110221